Cambridge, UK, 9 January 2020 – Microbiotica, a leading player in microbiome-based therapeutics, confirms its upcoming investor and scientific conference attendance during Q1 2020.
- Biotech Showcase 2020, 13-15 January 2020, San Francisco, US
Held during the week of the JPM Healthcare Conference in San Francisco, the conference provides private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Now in its 12th year, the Biotech Showcase features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings.
- Microbiotica’s CEO Mike Romanos will be presenting from 11:45am on 14 January at the Hilton Hotel on Union Square.
- LSX World Congress, 4-5 February 2020, London, UK
The sixth annual LSX World Congress will take place in London, bringing together executives from the biotech, medtech, healthtech and pharma industries, along with the sector’s most active investors, stakeholders and service companies. Mike Romanos will be participating in a panel discussing the growing trend of collaboration partnerships between pharma and biotech companies with platform technologies.
- Platforms and Partnerships Panel Discussion: 5 February 2020, 12:30 – Mike Romanos on panel
- Microbiome Movement – Drug Development Europe, 4-6 February 2020, London, UK
One of the key conference series for the microbiome industry, Microbiome Movement – Drug Development Europe is now in its fourth year. The conference will bring leading scientists from the biopharmaceutical and academic community to discuss the causal role of the microbiome in disease and the development of next-generation microbiome-targeted therapeutics. Mike Romanos and Trevor Lawley will both be speaking at the event.
- Microbiome Leaders Panel Discussion: 5 February, 8:30-9:30am – Mike Romanos on panel
- Rational Design of Gut Microbiome Biomarkers and LBTs to Optimize Cancer Immunotherapy: 6 February, 8:30-9:00am – talk by Trevor Lawley
- Current Innovation & Future Integration of Microbiome-Based Approaches into Routine Oncology Practice – Panel Discussion: 6 February, 10:00-10:30am – Trevor Lawley on panel
- Sachs European Life Sciences CEO Forum, 19-20 February 2020, Zurich, Switzerland
Now in its 13th year, the global bio-pharma industry forum addresses the main challenges for 2020 in investment and partnering. Key sector players contribute their insights in panels which cover the macro landscape as well as innovation and the latest breakthroughs in different therapeutic areas. Mike Romanos will be taking part in a panel at the event.
- Pharma DealMakers Roundtable: 20 February, 9:00-9:50am – Mike Romanos on panel
-ENDS-
Notes to Editors
About Microbiotica
Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute. The Company was founded by Dr Mike Romanos, Dr Trevor Lawley and Professor Gordon Dougan, FRS. Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute. It has a strategic collaboration with Genentech, a member of the Roche Group, in the field of inflammatory bowel disease (IBD) as well as with University of Adelaide to develop a defined product for ulcerative colitis.
Microbiotica has attracted £12m in equity investment from Cambridge Innovation Capital, IP Group plc and Seventure Partners.
For more information, please visit www.microbiotica.com, LinkedIn and Twitter.
About Microbiotica’s platform
The Microbiotica platform comprises the world’s leading microbiome Culture Collection and linked Reference Genome Database that enable unprecedented precision of gut bacterial identification The Company is adding to this at a very rapid rate through its industrial culturing and sequencing pipeline, providing the best available representation of clinical trial samples for strain-level identification of bacteria. The complex datasets that arise from such studies are analysed using AI techniques to discern microbiome signatures linked to phenotype. The availability of the physical Culture Collection enables biological evaluation of bacteria in proprietary translational models including humanised microbiome mouse models.
About the Microbiome
Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.
